Monoclonal antibodyFDA-approvedFirst-line
Pertuzumab
How it works
Blocks the HER2 receptor on cancer cells, preventing growth signals and inhibiting cell division.
Cancer types
Breast Cancer— HER2-positive
Efficacy
Studies show that combining pertuzumab with trastuzumab and chemotherapy can improve response rates and progression-free survival in HER2-positive patients.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Pertuzumab Improves Cancer Treatment Response in Early HER2+ Breast Cancer | Breast Cancer | meta-analysis | The pooled odds ratio showed significantly higher pathological complete response rates with dual HER2 blockade (OR: 1.81; 95% CI: 1.56-2.09) | Source → |
| Dual HER2 Blockade Improves Outcomes in HER2-Positive Breast Cancer | Breast Cancer | meta-analysis | The P + H arm showed significant improvements in 3-year EFS rate (RR 1.08, 95% CI 1.00-1.16, p = 0.04), 5-year EFS rate (RR 1.10, 95% CI 1.01-1.20, p = 0.03), and 5-year DFS rate (RR 1.09, 95% CI 0.99-1.20). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.